Skip to main content

Table 1 Chemotherapy regimens and adverse events in the present case

From: Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate

 

Chemotherapy

No.

Regimen

PS

BI

Grade of adverse event*

BW

(kg)

Complications

Neutropenia

FN or infecton

Anemia

Thrombocytopenia

Anorexia

Weight loss

Onset to 1st CR

Induction

1

BHAC 200 mg/m2 IV day 1-8

3

100

4

3

4

4

3

1

44.4

 

DNR 40 mg/m2 IV day 1-3

Consolidation

2

BHAC 200 mg/m2 IV day 1-5

2

100

4

3

4

4

3

1

41.6

Sepsis

MIT 7 mg/m2 IV day 1-3

 

3

BHAC 200 mg/m2 IV day 1-5

1

100

4

3

3

3

3

1

40.8

 

DNR 25 mg/m2 IV day 1-2

ETP 100 mg/m2 IV day 1-3

4

BHAC 200 mg/m2 IV day 1-5

1

100

4

3

2

2

2

1

40.5

 

ACR 10 mg/m2 IV day 1-5

1st relapse to 2nd CR

Induction

5

BHAC 200 mg/m2 IV day 1-8

4

55

4

3

4

3

3

2

39.0

Osteoporotic lumbar compression fracture Pulmonary Aspergillosis

DNR 40mg/m2 IV day 1-3

Consolidation

6

BHAC 200 mg/m2 IV day 1-6

2

100

4

3

3

2

2

2

38.5

 

DNR 40 mg/m2 IV day 1-3

 

7

Ara-C 1 g/m2 IV x2 day 1-5

1

100

4

3

4

3

3

3

36.9

 

2nd relapse to 3rd CR

Induction

8

LDAC day 1-14 with M-CSF day 15-28

3

100

4

3

3

4

3

3

36.5

 
 

9

LDAC day 1-14 with M-CSF day 1-14

2

100

4

None

3

4

3

3

34.9

 

Consolidation

10

Same as # 9

1

100

3

None

3

3

3

3

35.2

 
 

11

Same as # 9

1

100

3

None

3

3

3

3

36.4

 
 

12

Same as # 9

1

100

3

None

4

3

3

3

36.4

 
 

13

Same as # 9

1

100

2

None

3

3

3

2

37.5

 

3rd relapse to 4th CR

Induction

14

LDAC day 1-14 with M-CSF day 1-14

1

100

4

3

3

4

3

2

37.5

 

VPA 600 mg/day PO

15

LDAC day 1-12 with M-CSF day 1-14

1

100

3

None

3

3

3

   

VPA 600 mg/day PO

Consolidation

16

Same as # 15

1

100

3

None

3

3

3

1

41.3

 

17

LDAC day 1-10 with M-CSF day 1-14

1

100

3

3

2

3

3

2

39.1

 

VPA 600 mg/day PO

18

Same as # 17

1

100

3

3

2

3

3

2

39.4

 

19

Same as # 17

1

100

3

None

3

3

3

1

40.6

 

4th relapse to 5th CR

Induction

20

LDAC day 1-10 with M-CSF day 1-14

3

95

4

3

4

4

3

1

42.4

 

21

SPAC 200 mg/day PO day 1-14

1

95

None

None

3

None

2

   

G-CSF 100 μg SC day 1-14

22

Same as # 21

1

95

3

None

2

2

1

1

41.2

 

23

LDAC day 1-10 with M-CSF day 1-14

2

100

4

3

4

4

3

1

42.0

 

24

LDAC day 1-12 with M-CSF day 1-14

3

100

4

3

4

4

3

1

41.6

 

25

LDAC day 1-12 with G-CSF day 1-12

3

100

4

3

4

4

3

1

42.2

 

ACR 14 mg/m2 IV day 1-4

26

Same as # 25

2

100

3

3

3

3

3

1

41.7

 

Consolidation

27

Same as # 25

1

100

3

None

3

3

2

   

28

Same as # 25

1

100

4

None

3

3

2

2

39.6

 

29

Same as # 25

1

100

4

None

3

4

2

2

39.5

 

30

Same as # 25

1

100

4

None

3

4

2

   

5th relapse to 6th CR

Induction

31

LDAC day 1-12 with G-CSF day 1-12

3

5

4

3

4

4

3

1

40.8

Depression

ACR 14 mg/m2 IV day 1-4

32

MTX 15 mg + Ara-C 40mg + PSL 10mg IT day -1

4

5

4

3

4

4

4

  

Traumatic lumbar compression fracture

LDAC day 1-10 with G-CSF day 1-12

ACR 14 mg/m2 IV day 1-4

Consolidation

33

LDAC day 1-10 with G-CSF day 1-12

3

5

4

3

3

3

3

   

ACR 14 mg/m2 IV day 1-4

34

Same as # 33

1

75

4

None

3

3

3

None

44.0

 

35

Same as # 33

1

90

4

None

3

4

3

None

44.6

 

Maintenance

36

SPAC 300 mg/day PO day 1-7 every 4-6 weeks

1

100

None

None

None

None

2

2

36.0

Sarcopenia

  1. ACR: aclarubicin hydrochloride, Ara-C: cytarabine, BHAC; behenoyl cytarabine, BI: Barthel index, BW: body weight, DNR: daunorubicin hydrochloride, ETP: etoposide, FN: febrile neutropenia, G-CSF: lenograstim 100 μg subcutaneously injected or lenograstim 250 μg intravenously injected, IT: intrathecal injection, IV: intravenous injection, LDAC: cytarabine 10 mg/m2 subcutaneously injected twice a day, M-CSF: mirimostim 8 million units intravenously injected, MIT: mitoxantrone hydrochloride, PO: per oral, PS: performance status, SC: subctaneous injection.
  2. *Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 produced by the National Cancer Institute (http://evs.nci.nih.gov/ftp1/CTCAE/About.html).
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us